The same study also showed increased risk of progression to hip and knee OA in patients with diabetes, with or without obesity, who were exposed to GLP-1 agonists compared to patients with diabetes, with or without obesity, who were not exposed to GLP-1 agonists.58 The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.